← Leaderboards
George J Murphy
Harvard University (Medical School)
$5,671,947
Attributed
$15,347,119
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$15,347,119 · 6
By mechanism
U01$8,307,994 · 1
R01$6,888,353 · 4
F32$150,772 · 1
Top collaborators
- Martin H. Steinberg9 shared
- Rockland L Wiseman8 shared
- David H K Chui5 shared
- Gustavo Mostoslavsky5 shared
- David H Sherr5 shared
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Philip W Hinds$12,088,422
Others in their field
Top investigators on “Induced Pluripotent Stem Cell”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$77,143,245
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$72,554,837
- Joseph C Wu · Stanford University$63,140,589
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Linda M Brzustowicz · Rutgers The St Univ Of Nj New Brunswick$50,800,152
- Li-Huei Tsai · Massachusetts Institute Of Technology$37,797,465
Research focus
Induced Pluripotent Stem CellCellsAffectPharmaceutical PreparationsRegulationGeneticSignal PathwayStem CellsResponseGenesSerumTissuesErythroid CellsBaseErythroidBlood CellsBloodHemoglobinProductionTranscription FactorProteinsPathway InteractionsAmyloid FibrilsExtracellular
Grant awards (25)
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES$640,815
R01 · FY2023 · DK
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES$628,179
R01 · FY2022 · DK
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES$622,341
R01 · FY2021 · DK
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES$639,369
R01 · FY2020 · DK
Mechanisms of cis-acting HbF regulation in sickle cell anemia$426,000
R01 · FY2020 · HL · contact PI
Defining the Role of the AHR in Blood Cell Specifications$360,188
R01 · FY2020 · ES
Mechanisms of cis-acting HbF regulation in sickle cell anemia$426,000
R01 · FY2019 · HL · contact PI
Defining the Role of the AHR in Blood Cell Specifications$360,188
R01 · FY2019 · ES
Mechanisms of cis-acting HbF regulation in sickle cell anemia$425,875
R01 · FY2018 · HL · contact PI
Defining the Role of the AHR in Blood Cell Specifications$359,877
R01 · FY2018 · ES
Mechanisms of cis-acting HbF regulation in sickle cell anemia$444,000
R01 · FY2017 · HL · contact PI
Defining the Role of the AHR in Blood Cell Specifications$359,656
R01 · FY2017 · ES
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES$200,639
R01 · FY2017 · DK
Defining the Role of the AHR in Blood Cell Specifications$372,853
R01 · FY2016 · ES
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES$200,639
R01 · FY2016 · DK
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells$1,859,717
U01 · FY2015 · HL
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES$200,228
R01 · FY2015 · DK
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells$2,231,289
U01 · FY2014 · HL
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES$221,506
R01 · FY2014 · DK
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells$2,200,128
U01 · FY2013 · HL
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells$1,218,858
U01 · FY2012 · HL
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells$798,002
U01 · FY2011 · HL
Safer Vectors and Strategies For Gene Therapy$52,048
F32 · FY2007 · CA · contact PI
Safer Vectors and Strategies For Gene Therapy$50,428
F32 · FY2006 · CA · contact PI
Safer Vectors and Strategies For Gene Therapy$48,296
F32 · FY2005 · CA